Sign inJoin waitlistJoin the waitlist

RH

Roy S. Herbst

Chair Emeritus and Senior Advisor for the Lung-MAP Trial

Credentials: · · · ·

History

Yale School of Medicine
Present

Research

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
The Lancet · 2016 · First of 19 authors · Corresponding · 5,414 citations
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Nature · 2014 · First of 22 authors · 4,371 citations
The biology and management of non-small cell lung cancer
Review · Nature · 2018 · First of 3 authors · 3,939 citations

David Gandara
38 papers · 7 as a fellow
VP
Vassiliki Papadimitrakopoulou
36 papers
John Heymach
33 papers
WH
Waun Hong
31 papers
DR
David Rimm
30 papers
KK
Karen Kelly
30 papers
KS
Kurt Schalper
29 papers
AO
Amir Onn
28 papers
EK
Edward Kim
27 papers · 6 as a fellow
Scott Gettinger
27 papers
Sarah Goldberg
24 papers · 1 as a fellow
Frank Fossella
23 papers

Grants

Yale SPORE in Lung Cancer (YSILC): The Biology and Personalized Treatment of Lung Cancer
National Cancer Institute · P50
Contact PI · $23.7M · Yale University
2015–2030
Cancer Center Support Grant
National Cancer Institute · P30
Contact PI · $3.1M · Dartmouth College
1997–2029
Yale Cancer Center Advanced Training Program for Physician-Scientists (YCC-ATPP)
National Cancer Institute · T32
Contact PI · $2.6M · Yale University
2019–2029
NCI National Clinical Trials Network (NCTN) - Network Lead Academic Participating Sites
National Cancer Institute · UG1
Contact PI · $2.2M · Yale University
2019–2025

Clinical trials

S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer
Principal investigator · Terminated · Phase 3
SWOG Cancer Research Network
2009–2022
S0342: Paclitaxel, Carboplatin, and Cetuximab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Principal investigator · Completed · Phase 2
SWOG Cancer Research Network
2004–2011
PEG-interferon Alfa-2b in Treating Patients With Stage II, Stage III, or Stage IV Head and Neck Cancer That Can Be Removed By Surgery
Principal investigator · Completed · Phase 2
M.D. Anderson Cancer Center
2004–2006
Avastin and Tarceva for Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer
Principal investigator · Completed · Phase 1, Phase 2
M.D. Anderson Cancer Center
2002–2006